title: Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis.
abstract: OBJECTIVE
  To evaluate whether the quadrivalent human papillomavirus (HPV) (types 6, 11, 16, and 18) vaccine influences the clinical course of juvenile-onset recurrent respiratory papillomatosis (RRP) when administered to a group of patients with this condition.
  
  
  METHODS
  Uncontrolled intervention study of patients with juvenile-onset RRP examined at the Pediatric Otorhinolaryngology Clinic, Federal University of São Paulo, where nine patients between the ages of nine and 17 received three doses of the prophylactic quadrivalent HPV vaccine (Gardasil(®)) and were followed for one year. Disease staging, intervals between relapses, intervals between surgeries, and the number of surgeries during the year prior to vaccination and during the first year after vaccination were compared.
  
  
  RESULTS
  Eight patients were infected with HPV-6 and one with HPV-11. There were no statistically significant differences in the clinical scores (p=0.083), anatomical scores (p=0.257), intervals between relapses (p=0.062), intervals between surgeries (p=0.357), or the numbers of surgeries (p=0.180) when the years before and after vaccination were compared. All patients had relapses following vaccination.
  
  
  CONCLUSIONS
  Patients with juvenile-onset RRP experienced a similar clinical course in the year after versus the year before vaccination with Gardasil(®).
authors.affiliation: Discipline of Pediatric Otorhinolaryngology, Federal University of São Paulo, Brazil. Electronic address: j.sato.hermann@gmail.com.
authors.forename: Juliana Sato
authors.initials: JS
authors.lastname: Hermann
authors.affiliation: Department of Pediatrics, Federal University of São Paulo, Brazil.
authors.forename: Lily Yin
authors.initials: LY
authors.lastname: Weckx
authors.affiliation: Research Incentive Fund Association, Brazil.
authors.forename: Jussimara
authors.initials: J
authors.lastname: Monteiro Nürmberger
authors.affiliation: Research Incentive Fund Association, Brazil.
authors.forename: Gildo Francisco Dos
authors.initials: GF
authors.lastname: Santos Junior
authors.affiliation: Discipline of Infectious Diseases, Federal University of São Paulo, Brazil.
authors.forename: Antonio Carlos
authors.initials: AC
authors.lastname: Campos Pignatari
authors.affiliation: Discipline of Pediatric Otorhinolaryngology, Federal University of São Paulo, Brazil.
authors.forename: Shirley Shizue
authors.initials: SS
authors.lastname: Nagata Pignatari
mesh_terms: D000293:Adolescent; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000188:drug therapy*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
keywords: Child; Papilloma; Papillomavirus infections; Papillomavirus vaccines; Treatment outcome